Increased Density of Prohibitin-immunoreactive Oligodendrocytes in the Dorsolateral Prefrontal White Matter of Subjects with Schizophrenia Suggests Extraneuronal Roles for the Protein in the Disease

Overview

Journal Neuromolecular Med

Specialty Biochemistry

Date 2012 Jun 20

PMID 22711522

Citations 13

Authors

Hans-Gert Bernstein

Karl-Heinz Smalla

Diana Durrschmidt

Gerburg Keilhoff

Henrik Dobrowolny

Johann Steiner

Andrea Schmitt

Michael R Kreutz

Bernhard Bogerts

Affiliations

Soon will be listed here.

Abstract

Prohibitin has previously been implicated in the synaptic pathology of schizophrenia. The recently discovered abundant expression of prohibitin in human prefrontal oligodendrocytes raises the issue, whether this protein might also be part of the well-known white matter abnormalities in schizophrenia. Hence, post-mortem brains of ten patients with schizophrenia and ten matched control cases were investigated. Using a direct, 3D-counting technique we morphometrically analyzed the number and density of prohibitin-immunoreactive oligodendroglial cells in the left and right dorsolateral, anterior cingulate, and orbitofrontal cortex white matter. Additionally, we studied the prohibitin expression in different neuronal and non-neuronal cell populations in rat cell cultures. We could confirm the strong expression of prohibitin in oligodendrocytes. Intracellularly, the protein was localized to mitochondria and some cell nuclei. In schizophrenia, the numerical density of prohibitin-expressing oligodendrocytes was significantly increased in the right dorsolateral white matter area. Taking into consideration the dual intracellular localization of prohibitin in oligodendrocyte mitochondria and cell nuclei, one may suggest an involvement of the protein in mitochondrial dysfunction and/or cycle abnormalities in schizophrenia.

Citing Articles

Glial cell deficits are a key feature of schizophrenia: implications for neuronal circuit maintenance and histological differentiation from classical neurodegeneration.

Bernstein H, Nussbaumer M, Vasilevska V, Dobrowolny H, Nickl-Jockschat T, Guest P Mol Psychiatry. 2024; 30(3):1102-1116.

PMID: 39639174 PMC: 11835740. DOI: 10.1038/s41380-024-02861-6.

Prohibitins in neurodegeneration and mitochondrial homeostasis.

Fernandez-Abascal J, Artal-Sanz M Front Aging. 2022; 3:1043300.

PMID: 36404989 PMC: 9674034. DOI: 10.3389/fragi.2022.1043300.

Insights into myelin dysfunction in schizophrenia and bipolar disorder.

Valdes-Tovar M, Rodriguez-Ramirez A, Rodriguez-Cardenas L, Sotelo-Ramirez C, Camarena B, Sanabrais-Jimenez M World J Psychiatry. 2022; 12(2):264-285.

PMID: 35317338 PMC: 8900585. DOI: 10.5498/wjp.v12.i2.264.

Prohibitin S-Nitrosylation Is Required for the Neuroprotective Effect of Nitric Oxide in Neuronal Cultures.

Qu Y, Konrad C, Anderson C, Qian L, Yin T, Manfredi G J Neurosci. 2020; 40(16):3142-3151.

PMID: 32152200 PMC: 7159891. DOI: 10.1523/JNEUROSCI.1804-19.2020.

Myelination of parvalbumin interneurons: a parsimonious locus of pathophysiological convergence in schizophrenia.

Stedehouder J, Kushner S Mol Psychiatry. 2016; 22(1):4-12.

PMID: 27646261 PMC: 5414080. DOI: 10.1038/mp.2016.147.

References

Hoistad M, Segal D, Takahashi N, Sakurai T, Buxbaum J, Hof P . Linking white and grey matter in schizophrenia: oligodendrocyte and neuron pathology in the prefrontal cortex. Front Neuroanat. 2009; 3:9. PMC: 2713751. DOI: 10.3389/neuro.05.009.2009. View

Govekar R, DCruz A, Pathak K, Agarwal J, Dinshaw K, Chinoy R . Proteomic profiling of cancer of the gingivo-buccal complex: Identification of new differentially expressed markers. Proteomics Clin Appl. 2010; 3(12):1451-62. DOI: 10.1002/prca.200900023. View

Merkwirth C, Dargazanli S, Tatsuta T, Geimer S, Lower B, Wunderlich F . Prohibitins control cell proliferation and apoptosis by regulating OPA1-dependent cristae morphogenesis in mitochondria. Genes Dev. 2008; 22(4):476-88. PMC: 2238669. DOI: 10.1101/gad.460708. View

Yang Y, Fung S, Rothwell A, Tianmei S, Weickert C . Increased interstitial white matter neuron density in the dorsolateral prefrontal cortex of people with schizophrenia. Biol Psychiatry. 2010; 69(1):63-70. PMC: 3005941. DOI: 10.1016/j.biopsych.2010.08.020. View

Hof P, Haroutunian V, Friedrich Jr V, Byne W, Buitron C, Perl D . Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol Psychiatry. 2003; 53(12):1075-85. DOI: 10.1016/s0006-3223(03)00237-3. View

Bernstein H, Stanarius A, Baumann B, Henning H, Krell D, Danos P . Nitric oxide synthase-containing neurons in the human hypothalamus: reduced number of immunoreactive cells in the paraventricular nucleus of depressive patients and schizophrenics. Neuroscience. 1998; 83(3):867-75. DOI: 10.1016/s0306-4522(97)00461-2. View

Rezin G, Amboni G, Zugno A, Quevedo J, Streck E . Mitochondrial dysfunction and psychiatric disorders. Neurochem Res. 2008; 34(6):1021-9. DOI: 10.1007/s11064-008-9865-8. View

Mitkus S, Hyde T, Vakkalanka R, Kolachana B, Weinberger D, Kleinman J . Expression of oligodendrocyte-associated genes in dorsolateral prefrontal cortex of patients with schizophrenia. Schizophr Res. 2007; 98(1-3):129-38. PMC: 2259271. DOI: 10.1016/j.schres.2007.09.032. View

Glantz L, Gilmore J, Overstreet D, Salimi K, Lieberman J, Jarskog L . Pro-apoptotic Par-4 and dopamine D2 receptor in temporal cortex in schizophrenia, bipolar disorder and major depression. Schizophr Res. 2010; 118(1-3):292-9. PMC: 2856798. DOI: 10.1016/j.schres.2009.12.027. View

10.

Uranova N, Vostrikov V, Orlovskaya D, Rachmanova V . Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr Res. 2004; 67(2-3):269-75. DOI: 10.1016/S0920-9964(03)00181-6. View

11.

Martins-de-Souza D, Gattaz W, Schmitt A, Maccarrone G, Hunyadi-Gulyas E, Eberlin M . Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. J Psychiatr Res. 2008; 43(11):978-86. DOI: 10.1016/j.jpsychires.2008.11.006. View

12.

Walterfang M, Velakoulis D, Whitford T, Pantelis C . Understanding aberrant white matter development in schizophrenia: an avenue for therapy?. Expert Rev Neurother. 2011; 11(7):971-87. DOI: 10.1586/ern.11.76. View

13.

Novak G, Tallerico T . Nogo A, B and C expression in schizophrenia, depression and bipolar frontal cortex, and correlation of Nogo expression with CAA/TATC polymorphism in 3'-UTR. Brain Res. 2006; 1120(1):161-71. DOI: 10.1016/j.brainres.2006.08.071. View

14.

Bernstein H, Steiner J, Bogerts B . Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy. Expert Rev Neurother. 2009; 9(7):1059-71. DOI: 10.1586/ern.09.59. View

15.

Sripathi S, He W, Atkinson C, Smith J, Liu Z, Elledge B . Mitochondrial-nuclear communication by prohibitin shuttling under oxidative stress. Biochemistry. 2011; 50(39):8342-51. PMC: 5368234. DOI: 10.1021/bi2008933. View

16.

Schmitt A, Steyskal C, Bernstein H, Schneider-Axmann T, Parlapani E, Schaeffer E . Stereologic investigation of the posterior part of the hippocampus in schizophrenia. Acta Neuropathol. 2008; 117(4):395-407. DOI: 10.1007/s00401-008-0430-y. View

17.

Katsel P, Byne W, Roussos P, Tan W, Siever L, Haroutunian V . Astrocyte and glutamate markers in the superficial, deep, and white matter layers of the anterior cingulate gyrus in schizophrenia. Neuropsychopharmacology. 2011; 36(6):1171-7. PMC: 3077461. DOI: 10.1038/npp.2010.252. View

18.

Danos P, Baumann B, Kramer A, Bernstein H, Stauch R, Krell D . Volumes of association thalamic nuclei in schizophrenia: a postmortem study. Schizophr Res. 2003; 60(2-3):141-55. DOI: 10.1016/s0920-9964(02)00307-9. View

19.

Smalla K, Mikhaylova M, Sahin J, Bernstein H, Bogerts B, Schmitt A . A comparison of the synaptic proteome in human chronic schizophrenia and rat ketamine psychosis suggest that prohibitin is involved in the synaptic pathology of schizophrenia. Mol Psychiatry. 2008; 13(9):878-96. DOI: 10.1038/mp.2008.60. View

20.

Prabakaran S, Swatton J, Ryan M, Huffaker S, Huang J, Griffin J . Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry. 2004; 9(7):684-97, 643. DOI: 10.1038/sj.mp.4001511. View